Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Published: 16 April 2024| Version 1 | DOI: 10.17632/742wzhgpwz.1
Contributors:
Mingyue Wang, Xing-Hua Gao, Li Zhang

Description

The "Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis" publication uses these data as supplemental information. JAK1-selective inhibitors are widely used as small-molecule targeted agents for the treatment of patients with atopic dermatitis, in this study, we found that JAK1-selective inhibitor monotherapy was more efficacious than the combination, but the incidence of treatment-related adverse effects was subsequently elevated. More data are needed to investigate the efficacy and safety of selective JAK1 inhibitors in the future.

Files

Categories

Dermatology, Atopic Dermatitis, Janus Kinase

Licence